The BET inhibitor/degrader ARV-825 prolongs the growth arrest response to Fulvestrant + Palbociclib and suppresses proliferative recovery in ER-positive breast cancer

Anti-estrogens or aromatase inhibitors in combination with cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors are the current standard of care for estrogen receptor-positive (ER+) Her-2 negative metastatic breast cancer. Although these combination therapies prolong progression-free survival compare...

Descripción completa

Detalles Bibliográficos
Autores principales: Finnegan, Ryan M., Elshazly, Ahmed M., Patel, Nipa H., Tyutyunyk-Massey, Liliya, Tran, Tammy H., Kumarasamy, Vishnu, Knudsen, Erik S., Gewirtz, David A.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2023
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890056/
https://www.ncbi.nlm.nih.gov/pubmed/36741704
http://dx.doi.org/10.3389/fonc.2022.966441

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9890056/
https://www.ncbi.nlm.nih.gov/pubmed/36741704
http://dx.doi.org/10.3389/fonc.2022.966441

Ejemplares similares